Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
Status:
Not yet recruiting
Trial end date:
2027-09-30
Target enrollment:
Participant gender:
Summary
This is a Phase II, single-arm, open label study to evaluate Olaparib plus Pembrolizumab
following platinum-based chemotherapy plus Pembrolizumab as neoadjuvant therapy for germline
BRCA (gBRCA) 1/2 mutated triple negative breast cancer (TNBC).
Pembrolizumab in combination with weekly paclitaxel and carboplatin (treatment 1) is followed
by Pembrolizumab in combination with Olaparib (treatment 2) in neoadjuvant setting and
Pembrolizumab in combination with Olaparib in adjuvant setting will be studied